- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Biosergen AB: Bulletin from the annual general meeting of Biosergen AB | 98 | GlobeNewswire (Europe) | Biosergen AB reg. no. 559304-1295 ("Biosergen" or the "Company") held its annual general meeting today, 30 June 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the below resolutions... ► Artikel lesen | |
| Mo | The observation status for Biosergen AB is updated | 134 | GlobeNewswire | On April 10, 2026, the shares in Biosergen AB (the "Company") were given observation status with reference to information that the Company's board of directors had resolved to pause the development... ► Artikel lesen | |
| 26.06. | Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie | 966 | GlobeNewswire (Europe) | This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover... ► Artikel lesen | |
| 26.06. | Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie | 176 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 26.06. | BIOSERGEN AB: Biosergen Publishes 2025 Annual Report | 1 | Cision News | ||
| 26.06. | Flerie AB: Flerie and Biosergen have agreed on a merger plan - Flerie's first new investment since its listing on Nasdaq Stockholm | 196 | GlobeNewswire (Europe) | Today, on 26 June 2026, Flerie AB (publ) ("Flerie") and Biosergen AB ("Biosergen") (together the "Companies") jointly announce that the Board of Directors of Flerie and the Board of Directors of Biosergen... ► Artikel lesen | |
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 11.06. | Notice of annual general meeting in Biosergen AB | 2 | Cision News | ||
| 10.04. | Biosergen AB receives observation status | 304 | GlobeNewswire | On April 4, 2026, Biosergen AB ("the Company") disclosed that the Company's board of directors had resolved to pause the development of BSG005 and that the board of directors is exploring the possibility... ► Artikel lesen | |
| 04.04. | BIOSERGEN AB: Biosergen Pauses Development of BSG005 | 3 | Cision News | ||
| 10.02. | Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025 | 283 | GlobeNewswire (Europe) | February 10, 2026: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 01.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 01.12.2025 | 712 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.12.2025
Aktien
1 IT0005678104 Kaleon S.p.A.
2 IM00BYYPQX37... ► Artikel lesen | |
| 28.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.11.2025 | 1.256 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 28.11.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.11.2025ISIN NameCA38940L2057 GRAYCLIFF... ► Artikel lesen | |
| 28.11.25 | XFRA ISIN CHANGE | 562 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA60283T2074 Mineral Hill Industries Ltd. 28.11.2025 CA38077F1045 Gold Strategy Inc. 01.12.2025 Tausch 1:1US60855D3098 Moleculin... ► Artikel lesen | |
| 28.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2025 | 540 | Xetra Newsboard | Das Instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2025 und ex Kapitalmassnahme am 01.12.2025 The instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY is traded... ► Artikel lesen | |
| 27.11.25 | Reverse split and Change of ISIN for Biosergen AB | 400 | GlobeNewswire | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from Dec 1, 2025. The order book will not change.
Short... ► Artikel lesen | |
| 20.11.25 | Biosergen AB: Determination of Record Date for Reverse Share Split in Biosergen | 269 | GlobeNewswire (Europe) | STOCKHOLM, November 20, 2025. At the Annual General Meeting of Biosergen AB ("Biosergen" or the "Company") on June 11, 2025, a resolution was passed on a reverse split of shares, whereby one hundred... ► Artikel lesen | |
| 19.11.25 | Biosergen AB: Biosergen publishes interim report for the third quarter 2025 | 253 | GlobeNewswire (Europe) | November 19, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 20.08.25 | Biosergen AB: Biosergen publishes its interim report for the second quarter 2025 | 262 | GlobeNewswire (Europe) | Wednesday August 20, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the second quarter 2025. The interim report is available as an attached document and on... ► Artikel lesen | |
| 24.07.25 | Biosergen AB: Biosergen Appoints Mark Beveridge as Chief Financial Officer | 328 | GlobeNewswire (Europe) | Stockholm, Sweden - July 24, 2025 - Biosergen AB ("Biosergen" or the "Company"), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces the... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,92 | +0,01 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,200 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| IMMUNOVANT | 38,790 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,440 | +0,13 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RECURSION PHARMACEUTICALS | 3,815 | +0,39 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| TANGO THERAPEUTICS | 29,460 | 0,00 % | TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts | ||
| VOR BIOPHARMA | 20,600 | +0,05 % | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| OLEMA PHARMACEUTICALS | 12,640 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 26,510 | +0,04 % | ALUMIS INC. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 23,970 | 0,00 % | Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade | ||
| PRAXIS PRECISION MEDICINES | 318,37 | -0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ERASCA | 18,470 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| IMMUNOME | 23,620 | +0,04 % | TD Cowen bestätigt Kaufempfehlung für Argenx und verweist auf IMNM-Potenzial | ||
| DYNE THERAPEUTICS | 23,110 | +0,17 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| ADMA BIOLOGICS | 8,950 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen |
BIOSERGEN AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,625 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.